Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 3rd Annual H.C.

The consensus rating for Vanda Pharma is Buy, based on 2 analyst ratings. With an average one-year price target of $20.0, ...

Lexicon Pharmaceuticals, Inc.’s LXRX share price has dipped by 6.69%, which has investors questioning if this is right time to buy.

Short interest in Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) decreased during the last reporting period, falling from 43.88M to 41.33M. This put 31.81% of the company's publicly available shares short.